{"id":394,"date":"2017-08-04T18:20:53","date_gmt":"2017-08-04T16:20:53","guid":{"rendered":"https:\/\/www.pharmarte.com\/?p=394"},"modified":"2017-08-04T18:21:09","modified_gmt":"2017-08-04T16:21:09","slug":"randomized-multicenter-investigation-of-folate-plus-vitamin-b12-supplementation-inschizophrenia","status":"publish","type":"post","link":"https:\/\/www.pharmarte.com\/en\/randomized-multicenter-investigation-of-folate-plus-vitamin-b12-supplementation-inschizophrenia\/","title":{"rendered":"Randomized multicenter investigation of folate plus vitamin B12 supplementation inschizophrenia."},"content":{"rendered":"
\n
\n
\n
\n
\n

Roffman JL1<\/sup>,\u00a0Lamberti JS,\u00a0Achtyes E,\u00a0Macklin EA,\u00a0Galendez GC,\u00a0Raeke LH,\u00a0Silverstein NJ,\u00a0Smoller JW,\u00a0Hill M,\u00a0Goff DC.<\/p>\n

Abstract<\/h3>\n

IMPORTANCE:<\/h4>\n

More effective treatments are needed for negative symptoms of\u00a0schizophrenia, which are typically chronic, disabling, and costly. Negative symptoms have previously been associated with reduced blood\u00a0folate\u00a0levels, especially among patients with low-functioning variants in genes that regulate\u00a0folate\u00a0metabolism, suggesting the potential utility of\u00a0folate\u00a0supplementation.<\/p>\n

OBJECTIVES:<\/h4>\n

To determine whether folic acid\u00a0plus\u00a0vitamin\u00a0B12\u00a0supplementation\u00a0reduces negative symptoms ofschizophrenia\u00a0and whether functional variants in\u00a0folate-related genes influence treatment response.<\/p>\n

DESIGN:<\/h4>\n

Parallel-group,\u00a0randomized, double-blind, placebo-controlled clinical trial of 16 weeks of treatment with 2 mg of folic acid and 400\u00a0\u0e06\u0e2cg of\u00a0vitamin\u00a0B12.<\/p>\n

SETTING:<\/h4>\n

Three community mental health centers affiliated with academic medical centers in the United States.<\/p>\n

PARTICIPANTS:<\/h4>\n

Outpatients with chronic\u00a0schizophrenia\u00a0who were psychiatrically stable but displayed persistent symptoms despite antipsychotic treatment. Eligible patients were 18 to 68 years old, were treated with an antipsychotic agent for 6 months or more at a stable dose for 6 weeks or more, and scored 60 or more on the Positive and Negative Syndrome Scale.<\/p>\n

INTERVENTION:<\/h4>\n

One hundred forty subjects were\u00a0randomized\u00a0to receive daily oral folic acid\u00a0plus\u00a0vitamin\u00a0B12\u00a0or placebo.<\/p>\n

MAIN OUTCOME MEASURES:<\/h4>\n

Change in negative symptoms (Scale for the Assessment of Negative Symptoms [SANS]), as well as positive and total symptoms (Positive and Negative Syndrome Scale).<\/p>\n

RESULTS:<\/h4>\n

Folate\u00a0plus\u00a0vitamin\u00a0B12\u00a0improved negative symptoms significantly compared with placebo (group difference, -0.33 change in SANS score per week; 95% CI, -0.62 to -0.05) when genotype was taken into account but not when genotype was excluded. An interaction of the 484C>T variant of FOLH1 (rs202676) with treatment was observed (P = .02), where only patients homozygous for the 484T allele demonstrated significantly greater benefit with active treatment (-0.59 change in SANS score per week; 95% CI, -0.99 to -0.18). In parallel, we observed an inverse relationship between red blood cell\u00a0folate\u00a0concentration at baseline and 484C allele load (P = .03), which persisted until 8 weeks of treatment. Change in positive and total symptoms did not differ between treatment groups.<\/p>\n

CONCLUSIONS:<\/h4>\n

Folate\u00a0plus\u00a0vitamin\u00a0B12\u00a0supplementation\u00a0can improve negative symptoms of\u00a0schizophrenia, but treatment response is influenced by genetic variation in\u00a0folate\u00a0absorption. These findings support a personalized medicine approach for the treatment of negative symptoms.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Roffman JL1,\u00a0Lamberti JS,\u00a0Achtyes E,\u00a0Macklin EA,\u00a0Galendez GC,\u00a0Raeke LH,\u00a0Silverstein NJ,\u00a0Smoller JW,\u00a0Hill M,\u00a0Goff DC. Abstract IMPORTANCE: More effective treatments are needed for negative symptoms of\u00a0schizophrenia, which are typically chronic, [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42],"tags":[],"class_list":["post-394","post","type-post","status-publish","format-standard","hentry","category-bibliografia-mthfr-prevent-plus"],"_links":{"self":[{"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/posts\/394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/comments?post=394"}],"version-history":[{"count":1,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/posts\/394\/revisions"}],"predecessor-version":[{"id":395,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/posts\/394\/revisions\/395"}],"wp:attachment":[{"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/media?parent=394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/categories?post=394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmarte.com\/en\/wp-json\/wp\/v2\/tags?post=394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}